胡以国的个人简介
胡以国，四川大学华西医院研究员。
人物经历
教育经历：
1.2002/9u20132007/8，University of Maine，生物化学与分子生物学，博士，
2.1994/9u20131999/7，北京医科大学，基础医学，学士，
科研与学术工作经历：
1.2015/4-至今，四川大学，生物治疗国家重点实验室，研究员
2.2008/8-2015/3，哈佛医学院，博士后
科研方向
1、血液干细胞分化与衰老?
2、慢性粒细胞白血病
3、多发性骨髓瘤
著述成果
一、期刊论文
1. 第一作者论文：
1) Yiguo Hu*, Shaoguang Li，Survival regulation of leukemia stem cells. Cell Mol Life Sci，2016，73（5）：1039-1050
2) Hu Y, Song W, Lu D, Cirstea D, Munshi NC, Anderson KC. CSNK1?1 mediates malignant plasma cell survival. Leukemia. 2014 Jun 25. Leukemia，2015，29（2）：474-482. doi: 10.1038/leu.2014.202.
3) Yiguo Hu*. Acute Lymphoblastic Leukemia: Genetic Events and Molecular Signatures. Am. J. Biomed. Sci. 2014, 6(4), 238-253; doi: 10.5099/aj140400238
4) Hu Y, Zheng M, Gali R, Tian Z, Topal G?rgün G, Munshi NC, Mitsiades CS, Anderson KC. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J. 2013 Nov 1;3:e156.
5) Hu Y, Chen Y and Li S. ?beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR/ABL-induced chronic myeloid leukemia. Leukemia 2009 Jan;23(1):109-16.
6) Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006. 103(45):16870-16875.
7) Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Van Etten RA, Li S. 2004. Requirement for Src kinases for BCR/ABL-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genet 36(5):453-461.
2. 非第一作者及通讯作者论文：
1) Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, Ní Chonghaile T, Johncilla ME, Tai YT, Cheng JQ, Letai A, Munshi NC, Anderson KC, Carrasco RD. Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma。 Cancer Res. 2015 Aug 6. pii: canres.0457.2015. [Epub ahead of print]
2) Tian Z, D’Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30;123(5):706-16.
3) Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 Mar;28(3):680-9.
4) Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
5) Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC.Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 8;120 (19):3958-67.
6) Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 1;18(17):4669-81.
7) Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, Miron P, Zhang X, Brehm MA, Li D, Green MR, Li S. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012 Jul 15;44(8):861-71.
8) Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30;120(9):1877-87.
9) Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14;119(24):5772-81.
10) Sullivan C, Chen Y, Shan Y, Hu Y, Peng C, Zhang H, Kong L, Li S. Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. PLoS One. 2011;6(10):e26246.
11) Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D, Li S. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 2011 Jul 14;118(2):390-400.
12) Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71.
13) G?rgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28;116(17):3227-37.
14) G?rgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24;115(25):5202-13.
15) Chen Y, Hu Y, Zhang H, Peng C, Li S.Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009 Jul;41(7):783-92.
16) Peng C, Brain J, Hu Y, Kong L, Goodrich A, Grayzel D, Read M, Pak R, Li S. 2007. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110:678-685.
17) Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten R. 2006. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One Dec 20;1:e18.
18) Pelletier S, Hong D, Hu Y, Liu Y, Li S. 2004. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerates the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice. Blood 104(7):2163-71.
Book Chapter:
Yiguo Hu, Shaoguang Li. Genetic modeling of human blood cancers in mice. Mouse Models of Human Blood Cancers edited by Shaoguang Li, DOI:10.1007/978-0-378-69132-9_2, ? Springer Science + Business Media, LLC 2008
Lecture:
The 45th annual meeting of the American Society of Hematology, San Diego, 2003.
Title: Src family kinases are utilized by the BCR/ABL oncogene to induce B-cell acute lymphoblastic leukemia (B-ALL) but not chronic myeloid leukemia (CML) in mice
Awards:
2003 Travel award to attend ASH meeting (San Diego, CA U.S.A.)
2005 Travel award to attend ASH meeting (Atlantic, GA U.S.A)
Reviewer of Scientific Journals:
International Journal of Cancer, Hematologica, oncotarget。
